4D Molecular Therapeutics, Inc. Quality Score

4D Molecular Therapeutics scores 40 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which rates it a mixed business on these measures. Recent figures include a -214.2% operating margin and a -33.9% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.

Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from FDMT's SEC filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where 4D Molecular Therapeutics scores well and where it falls behind.

4D Molecular Therapeutics earns about -33.9% on its invested capital, which is weak. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to FDMT's margins and growth on this scorecard to judge durability.

4D Molecular Therapeutics runs an operating margin of about -214.2% and a net margin of about -194.7%. Revenue has grown at roughly 44.3% a year recently. High, stable margins usually point to pricing power and operating discipline. Margins are most telling next to growth and returns on capital, all of which feed this quality score. This is analysis from SEC filings, not investment advice.